TOKYO, Oct 24 (Reuters) - Takeda Pharmaceutical Co. (4502.T: Quote, NEWS, Research), Japan’s biggest drug maker, said on Tuesday it had ended its licensing and development agreement with BioNumerik Pharmaceuticals Inc. (BNPI.O: Quote, Profile, Research) for the chemoprotective agent Tavocept.
